Twenty-year Patient-reported Outcomes After Surgery, Radiotherapy, or Brachytherapy for Localized Prostate Cancer

Our study presents new results over a period of 20 years after treatment for localized prostate cancer, including differences that are important for shared decision-making. The greatest urinary incontinence occurred after radical prostatectomy, and the least deterioration in sexual function occurred...

ver descrição completa

Detalhes bibliográficos
Autores: Zamora, Víctor|||0000-0003-2061-0052, Garin, Olatz|||0000-0001-6193-0779, Suárez, José Francisco|||0000-0001-6427-4391, Guedea, Ferran|||0000-0001-8798-8696, Pont, Angels|||0000-0002-0602-552X, Pardo Cladellas, Yolanda|||0000-0003-4982-5495, Goñi, Alai|||0000-0002-6365-9617, Mariño, Alfonso|||0000-0002-6720-3916, Hervás Morón, Asunción|||0000-0002-7439-1820, Herruzo, Ismael, Cabrera, Patricia|||0000-0001-6050-7354, Sancho-Pardo, Gemma|||0000-0003-2266-6172, Ponce de León Roca, Javier|||0000-0003-0250-2533, Macías Hernández, Víctor|||0000-0003-2904-5715, Gutiérrez, Cristina|||0000-0003-2626-1957, Castells, Manuel, Ferrer Forés, Maria Montserrat|||0000-0001-9867-7391
Tipo de documento: artigo
Data de publicação:2025
País:España
Recursos:Universitat Autònoma de Barcelona
Repositório:Dipòsit Digital de Documents de la UAB
Idioma:inglês
OAI Identifier:oai:dnet:uabarcelona_::aeeb72892c4565624472acf111c22577
Acesso em linha:https://ddd.uab.cat/record/327838
https://dx.doi.org/urn:doi:10.1016/j.euros.2025.10.007
Access Level:Acceso aberto
Palavra-chave:Comparative effectiveness
Localized prostate cancer
Patient-reported outcome measures
External radiotherapy
Radical prostatectomy
Brachytherapy
Descrição
Resumo:Our study presents new results over a period of 20 years after treatment for localized prostate cancer, including differences that are important for shared decision-making. The greatest urinary incontinence occurred after radical prostatectomy, and the least deterioration in sexual function occurred after brachytherapy. Our objective was to compare the impact of open radical prostatectomy (RP), external beam radiotherapy (EBRT), and brachytherapy in patients with localized prostate cancer via patient-reported outcome measures up to 20 yr after treatment. This was a prospective observational study (ClinicalTrials.gov ) of men with localized prostate cancer (clinical stage T1-T2, low or intermediate risk). The Expanded Prostate Cancer Index Composite (EPIC-26) and Short Form-36 (SF-36) questionnaires were centrally administered via telephone interviews before treatment and then annually after treatment. Generalized estimating equation models were constructed with propensity score-based weights. The RP group reported gradual, statistically significant worsening for almost all EPIC-26 and SF-36 scores at most follow-up time points. Significantly lower urinary incontinence deterioration was observed in both radiotherapy groups than after RP. Urinary irritative/obstructive, sexual, bowel, and hormonal symptom patterns were similar regardless of treatment, except for less sexual deterioration in the brachytherapy group. The observational design is the main limitation, but propensity score weights mitigated treatment selection bias. Our findings provide detailed novel evidence, measured over 20 yr, on the long-term impact of disease and treatment on patients with localized prostate cancer. While all treatment groups showed a general deterioration over time, important differences in urinary incontinence (highest after RP) and sexual decline (least after brachytherapy) persisted at 20 yr, and these should be incorporated into shared decision-making processes. Our study provides new findings on outcomes of treatment for localized prostate cancer as reported by patients over a period of up to 20 years. There was a general deterioration over time, but worse urinary incontinence after radical prostatectomy and the lowest decline in sexual function after brachytherapy persisted over time. These findings can inform patients during shared decision-making on the most suitable treatment for localized prostate cancer.